Biogened (WAR:BGD) Other Operating Expense: zł1.7 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:BGD Biogened SA WAR:BGD
74 GF Score
Price zł19.90
GF Value zł24.34
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biogened Other Operating Expense?

Biogened WAR:BGD 74 Other Operating Expense is zł1.7 Mil as of Jun. 2026. GuruFocus rates WAR:BGD with a GF Score™ of 74/100 and a GF Value™ of zł24.34 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Biogened's Other Operating Expense for the three months ended in Jun. 2026 was zł1.5 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was zł1.7 Mil.

Biogened's quarterly Other Operating Expense declined from Dec. 2025 (zł0.2 Mil) to Mar. 2026 (zł-0.1 Mil) but then increased from Mar. 2026 (zł-0.1 Mil) to Jun. 2026 (zł1.5 Mil).

Biogened's annual Other Operating Expense increased from Dec. 2023 (zł0.7 Mil) to Dec. 2024 (zł0.7 Mil) but then declined from Dec. 2024 (zł0.7 Mil) to Dec. 2025 (zł0.3 Mil).

Biogened Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Biogened's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogened Other Operating Expense Chart

Biogened Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.16 7.20 0.70 0.72 0.31

Biogened Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.15 -0.06 1.52
WAR:BGD
74GF Score
Biogened SA WAR:BGD
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogened Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł1.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of zł1.7 Mil mean?
Biogened (WAR:BGD) has a Other Operating Expense of zł1.7 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Biogened and its competitors.
Is Biogened's Other Operating Expense too high?
Biogened's current Other Operating Expense is zł1.7 Mil. Overall, Biogened has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's Other Operating Expense compare to ZTS and UTHR?
Biogened's Other Operating Expense of zł1.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Biogened and its competitors. Biogened's current Other Operating Expense is zł1.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł24.34, compared to a current price of zł19.90 — trading 18.2% below its estimated fair value. The current Other Operating Expense is zł1.7 Mil. Biogened's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Biogened (WAR:BGD), the current Other Operating Expense is zł1.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogened (WAR:BGD) Overvalued in 2026?

Based on GuruFocus' analysis, Biogened stock appears to be undervalued. The current stock price of zł19.90 is trading 18.2% below its estimated GF Value™ of zł24.34. GuruFocus considers Biogened to be Modestly Undervalued.

Key valuation signals for WAR:BGD:

  • Other Operating Expense: zł1.7 Mil
  • GF Value™: zł24.34 vs. price of zł19.90 (18.2% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogened Business Description

Address Ulica Pojezierska 99, Lodz, POL, 91-342
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
74GF Score

Get the complete analysis for WAR:BGD

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.90
Price
zł24.34
GF Value